Nigeria's Pharmaceutical Industry Confronts Import Dependence and Supply Chain Challenges
Nigeria's pharmaceutical industry is experiencing a significant rise in demand, yet the sector continues to struggle with profound challenges, including heavy reliance on imports, elevated production costs, fragile supply chains, and the pervasive threat of counterfeit medications. Across the African continent, experts estimate that between 70 percent and 95 percent of medicines utilized are imported, while approximately 30 percent to 60 percent of pharmaceutical manufacturing capacity remains underutilized or idle. These statistics highlight a critical disparity between the escalating healthcare needs and the limited local production capabilities, underscoring a pressing issue for regional health security.
Pharma West Africa 2026: A Platform for Dialogue and Solutions
These pressing concerns were central to the discussions at the third edition of Pharma West Africa 2026, a comprehensive three-day exhibition and conference held at the Landmark Event Centre in Lagos. The event served as a vital gathering point for policymakers, manufacturers, researchers, investors, and health professionals, all united in their mission to explore strategies for securing medicine supply in West Africa. Participants focused on enhancing local production, improving financing mechanisms, and streamlining supply systems to foster self-sufficiency.
The conference was notably well-attended, drawing hundreds of delegates from various sectors, including representatives from global pharmaceutical companies and official delegations from the United Kingdom, India, and the St Petersburg region of Russia. Under the theme "Pharmaceutical Supply Chain Strengthening for Self-Sufficiency in West Africa," the event emphasized the urgent need to reduce dependency on imported medicines and to build more resilient healthcare infrastructures across the region.
Key Obstacles to Local Manufacturing Growth
Stakeholders at the conference identified several key factors that have hindered the growth of local pharmaceutical manufacturing in many African nations. These include:
- Donor dependency, which often leads to inconsistent funding and support.
- Fragmented procurement systems that complicate the acquisition of raw materials and equipment.
- Poor investment flows into the sector, limiting expansion and innovation.
Ahmed Yakasai, Chairman of the planning committee and former President of the Pharmaceutical Society of Nigeria, highlighted the lessons learned from the COVID-19 pandemic. He noted that the crisis exposed severe weaknesses in global supply chains and demonstrated the significant risks associated with over-reliance on foreign systems for essential medicines. This revelation has spurred calls for more robust, locally-driven solutions to ensure medication accessibility and affordability.
In summary, while Nigeria's pharmaceutical industry faces mounting demand, it must overcome substantial hurdles such as import dependence and supply chain inefficiencies to achieve sustainable growth and better serve the healthcare needs of its population.
